Mahale N et al., 2021-08: Indian case series of 50 hypoxic COVID-19 patients given intravenous methylene blue 1 mg/kg (max five doses) as rescue therapy: oxygenation improved and 30 of 50 were discharged, with no major adverse events, but there was no control group.
Intravenous MB was administered as rescue therapy in dosage of 1 mg/kg body weight, with a maximum of five doses, to patients with high oxygen requirements (SpO2/FiO2 <200) apart from the standard of care after obtaining G6PD levels.
Abstract
Mahale N et al., 2021-08: Indian case series of 50 hypoxic COVID-19 patients given intravenous methylene blue 1 mg/kg (max five doses) as rescue therapy: oxygenation improved and 30 of 50 were discharged, with no major adverse events, but there was no control group. Study type: retrospective case series (no control). N=50, tertiary hospital, India (June-September 2020). MB 1 mg/kg IV, maximum five doses, given after G6PD testing. Outcomes: SpO2/FiO2 improved from median 132.5 to 284; 6 needed invasive ventilation; 30 discharged (60%), 20 died. Adverse events: none reported. Funding: 'Source of support: Nil'; conflicts: none. Caveat: 40% mortality in an uncontrolled series cannot be attributed to or against the drug. Study type: uncontrolled series.
